Story perspectives

Boston Scientific Sees 60% Rise in Atrial Fibrillation Treatments

1/16/2025

50 7

Summary

Story summary

Boston Scientific predicts that over 60% of global atrial fibrillation procedures will utilize pulsed field ablation (PFA) by 2026.
CEO Mike Mahoney aims to position the company as the second-largest player in electrophysiology by mid-2025.
The Farapulse PFA device has boosted electrophysiology sales by 177%, totaling $527 million.
Expansion plans include markets in China, Japan, and the U.S., alongside increased mapping system usage.
The left atrial appendage closure market is expected to surpass $6 billion by 2030.

1 of 1

Story summary

Boston Scientific predicts that over 60% of global atrial fibrillation procedures will utilize pulsed field ablation (PFA) by 2026.
CEO Mike Mahoney aims to position the company as the second-largest player in electrophysiology by mid-2025.
The Farapulse PFA device has boosted electrophysiology sales by 177%, totaling $527 million.
Expansion plans include markets in China, Japan, and the U.S., alongside increased mapping system usage.
The left atrial appendage closure market is expected to surpass $6 billion by 2030.